Identification

Name
Levetiracetam
Accession Number
DB01202  (APRD01068)
Type
Small Molecule
Groups
Approved, Investigational
Description

Levetiracetam is an anticonvulsant medication used to treat epilepsy. Levetiracetam may selectively prevent hypersynchronization of epileptiform burst firing and propagation of seizure activity. Levetiracetam binds to the synaptic vesicle protein SV2A, which is thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice.

Structure
Thumb
Synonyms
  • Levetiracetam
  • Levetiracetame
  • Levetiracetamum
  • Levitiracetam
External IDs
N03AX14 / UCB 22059 / UCB L059 / UCB-22059 / UCB-L059
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LevetiracetamTablet250 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Act LevetiracetamTablet750 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Act LevetiracetamTablet500 mgOralActavis Pharma Company2005-12-07Not applicableCanada
Elepsia XRTablet, extended release1000 mg/1OralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
Elepsia XRTablet, extended release1500 mg/1OralSun Pharma Advanced Research Company Limited2015-03-13Not applicableUs
KeppraTablet, film coated750 mg/1OralPhysicians Total Care, Inc.2005-04-15Not applicableUs50474 0596 40 nlmimage10 04160230
KeppraTablet, film coated750 mg/1OralStat Rx USA2000-04-242018-02-08Us
KeppraTablet, film coated750 mg/1OralUcb Inc2000-04-24Not applicableUs
KeppraTablet, film coated500 mg/1OralMckesson Rxpak Inc2000-04-24Not applicableUs
KeppraTablet750 mg/1OralUCB Farchim S.A.2000-04-242016-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-levetiracetamTablet750 mgOralAbbott2014-05-302015-12-31Canada
Abbott-levetiracetamTablet500 mgOralAbbott2014-05-302015-12-31Canada
Abbott-levetiracetamTablet250 mgOralAbbott2014-05-302015-12-31Canada
Apo-levetiracetamTablet750 mgOralApotex Corporation2006-10-20Not applicableCanada
Apo-levetiracetamTablet500 mgOralApotex Corporation2006-10-20Not applicableCanada
Apo-levetiracetamTablet250 mgOralApotex Corporation2006-10-20Not applicableCanada
Auro-levetiracetamTablet750 mgOralAuro Pharma Inc2012-02-14Not applicableCanada
Auro-levetiracetamTablet500 mgOralAuro Pharma Inc2012-03-15Not applicableCanada
Auro-levetiracetamTablet250 mgOralAuro Pharma Inc2012-02-14Not applicableCanada
Ava-levetiracetamTablet500 mgOralAvanstra Inc2011-10-112014-08-21Canada
Categories
UNII
44YRR34555
CAS number
102767-28-2
Weight
Average: 170.212
Monoisotopic: 170.105527699
Chemical Formula
C8H14N2O2
InChI Key
HPHUVLMMVZITSG-LURJTMIESA-N
InChI
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
IUPAC Name
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
SMILES
CC[C@H](N1CCCC1=O)C(N)=O

Pharmacology

Indication

Used as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests. Protection was observed, however, against secondarily generalized activity from focal seizures induced by pilocarpine and kainic acid, two chemoconvulsants that induce seizures that mimic some features of human complex partial seizures with secondary generalization. Levetiracetam also displayed inhibitory properties in the kindling model in rats, another model of human complex partial seizures, both during kindling development and in the fully kindled state. The predictive value of these animal models for specific types of human epilepsy is uncertain. Levetiracetam is thought to stimulate synaptic vesicle protein 2A (SV2A), inhibiting neurotransmitter release.

TargetActionsOrganism
ASynaptic vesicle glycoprotein 2A
agonist
Human
AVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
Absorption

Rapidly and almost completely absorbed after oral administration (99%). Peak plasma concentrations occurring in about an hour following oral administration in fasted subjects.

Volume of distribution
Not Available
Protein binding

Very low (<10%)

Metabolism

The major metabolic pathway of levetiracetam (24% of dose) is an enzymatic hydrolysis of the acetamide group. No CYP450 metabolism detected.

Route of elimination

Sixty-six percent (66%) of the dose is renally excreted unchanged. The metabolites have no known pharmacological activity and are renally excreted. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption.

Half life

6-8 hours

Clearance
  • 0.96 mL/min/kg
Toxicity

Side effects include aggression, agitation, coma, drowsiness, reduced consciousness, slowed breathing

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Levetiracetam.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Levetiracetam.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levetiracetam.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Levetiracetam.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levetiracetam.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levetiracetam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levetiracetam.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Levetiracetam.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levetiracetam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amperozide.Experimental
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Levetiracetam.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Levetiracetam.Approved, Investigational
ApalutamideThe serum concentration of Levetiracetam can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Levetiracetam.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Levetiracetam.Approved
ArticaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levetiracetam.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Azaperone.Investigational, Vet Approved
AzelastineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levetiracetam.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Levetiracetam.Experimental
BarbexacloneThe metabolism of Levetiracetam can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Levetiracetam.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Levetiracetam.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Levetiracetam.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Levetiracetam.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levetiracetam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levetiracetam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Levetiracetam.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Levetiracetam.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Bupivacaine.Approved, Investigational
BuprenorphineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levetiracetam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levetiracetam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Levetiracetam.Approved
ButethalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Levetiracetam.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Levetiracetam.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Levetiracetam.Experimental
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levetiracetam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levetiracetam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Levetiracetam.Approved, Investigational
CaseinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Levetiracetam.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Levetiracetam.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levetiracetam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levetiracetam.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chloroprocaine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Levetiracetam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Levetiracetam.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levetiracetam.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levetiracetam.Approved
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Levetiracetam.Approved, Investigational
CimetidineThe serum concentration of Levetiracetam can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Levetiracetam.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levetiracetam.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Levetiracetam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levetiracetam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levetiracetam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Levetiracetam.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levetiracetam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Clothiapine.Experimental
ClotrimazoleThe therapeutic efficacy of Clotrimazole can be increased when used in combination with Levetiracetam.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levetiracetam.Approved
CocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levetiracetam.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Levetiracetam.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levetiracetam.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levetiracetam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levetiracetam.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levetiracetam.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Levetiracetam.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levetiracetam.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Levetiracetam.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levetiracetam.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Levetiracetam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levetiracetam.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levetiracetam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Levetiracetam.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Levetiracetam.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Levetiracetam.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Levetiracetam is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Levetiracetam.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Levetiracetam.Approved
EcopipamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Levetiracetam can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Levetiracetam.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levetiracetam.Approved, Investigational
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Levetiracetam.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levetiracetam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levetiracetam.Approved, Investigational
EthanolLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levetiracetam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levetiracetam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levetiracetam.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levetiracetam.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Levetiracetam.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levetiracetam.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluanisone.Experimental
FluconazoleThe therapeutic efficacy of Fluconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Levetiracetam.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levetiracetam.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levetiracetam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levetiracetam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levetiracetam.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Levetiracetam.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levetiracetam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levetiracetam.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Levetiracetam.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Levetiracetam.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levetiracetam.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Levetiracetam.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Levetiracetam.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Hexobarbital.Approved
HydrocodoneLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levetiracetam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levetiracetam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Levetiracetam.Withdrawn
IsavuconazoleThe serum concentration of Levetiracetam can be increased when it is combined with Isavuconazole.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Levetiracetam.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levetiracetam.Approved, Vet Approved
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levetiracetam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe therapeutic efficacy of Ketoconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Levetiracetam.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levetiracetam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Levetiracetam.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Levetiracetam can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Levetiracetam.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levetiracetam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.Approved
LumacaftorThe serum concentration of Levetiracetam can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Levetiracetam can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levetiracetam.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levetiracetam.Approved
MedazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Levetiracetam.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levetiracetam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levetiracetam.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levetiracetam.Approved
MethotrexateLevetiracetam may decrease the excretion rate of Methotrexate which could result in a higher serum level.Approved
MethotrimeprazineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methylphenobarbital.Approved
MetyrosineLevetiracetam may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Levetiracetam.Experimental
MianserinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Levetiracetam.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levetiracetam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Levetiracetam.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
MirtazapineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Levetiracetam.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levetiracetam.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Levetiracetam.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
NafcillinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Levetiracetam.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levetiracetam.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Levetiracetam.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nefazodone.Approved, Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Levetiracetam.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Levetiracetam.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Levetiracetam.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Levetiracetam.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Levetiracetam.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levetiracetam.Approved
NitroprussideLevetiracetam may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levetiracetam.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Levetiracetam.Approved
NordazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levetiracetam.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Levetiracetam.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levetiracetam.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Levetiracetam.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Levetiracetam can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levetiracetam.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Levetiracetam.Approved
OxprenololThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levetiracetam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levetiracetam.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Levetiracetam.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levetiracetam.Approved
ParaldehydeLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Levetiracetam.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levetiracetam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levetiracetam.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
PerazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levetiracetam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levetiracetam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Levetiracetam.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Levetiracetam.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Levetiracetam.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Levetiracetam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Levetiracetam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Levetiracetam can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
PramipexoleLevetiracetam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Levetiracetam.Approved
PregabalinThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Levetiracetam.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levetiracetam.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Levetiracetam.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Levetiracetam.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Levetiracetam.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levetiracetam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levetiracetam.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Levetiracetam is combined with PSD502.Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Levetiracetam.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levetiracetam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Levetiracetam.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Quinisocaine.Experimental
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Levetiracetam.Approved
RacloprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Levetiracetam.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam.Approved, Investigational
RanolazineThe serum concentration of Levetiracetam can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levetiracetam.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Levetiracetam.Approved, Investigational
RifampicinThe risk or severity of hypotension can be increased when Rifampicin is combined with Levetiracetam.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Levetiracetam.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Levetiracetam.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Romifidine.Vet Approved
RopiniroleLevetiracetam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ropivacaine.Approved
RotigotineLevetiracetam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levetiracetam.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Levetiracetam.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levetiracetam.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levetiracetam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levetiracetam.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Levetiracetam.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Levetiracetam.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Levetiracetam.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
StiripentolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Levetiracetam.Approved
SulpirideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sultopride.Experimental
SuvorexantLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Levetiracetam.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Levetiracetam.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levetiracetam.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Levetiracetam.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Levetiracetam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tetrodotoxin.Investigational
ThalidomideLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Levetiracetam.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levetiracetam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levetiracetam.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Levetiracetam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levetiracetam.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Levetiracetam.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levetiracetam.Approved, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Levetiracetam.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levetiracetam.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Levetiracetam.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Levetiracetam.Approved, Investigational, Vet Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levetiracetam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levetiracetam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levetiracetam.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Levetiracetam.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Levetiracetam.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levetiracetam.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levetiracetam.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Levetiracetam.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Levetiracetam can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Levetiracetam.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levetiracetam.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vinyl ether.Experimental
VoriconazoleThe therapeutic efficacy of Voriconazole can be increased when used in combination with Levetiracetam.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vortioxetine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Levetiracetam.Experimental
XenonThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Levetiracetam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Zolazepam.Vet Approved
ZolpidemLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levetiracetam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levetiracetam.Approved, Investigational
Food Interactions
  • Take without regard to meals. Food does not affect bioavailabilty.

References

Synthesis Reference

Tooru Futagawa, Jean-Pierre Canvat, Emile Cavoy, Michel Deleers, Michel Hamende, Vincent Zimmermann, "Process for the preparation of levetiracetam." U.S. Patent US6107492, issued September, 1996.

US6107492
General References
Not Available
External Links
KEGG Drug
D00709
KEGG Compound
C07841
PubChem Compound
5284583
PubChem Substance
46508406
ChemSpider
4447633
BindingDB
50422542
ChEBI
6437
ChEMBL
CHEMBL1286
Therapeutic Targets Database
DAP000502
PharmGKB
PA450206
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Levetiracetam
ATC Codes
N03AX14 — Levetiracetam
AHFS Codes
  • 28:12.92 — Miscellaneous Anticonvulsants
FDA label
Download (52.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAphasia / Strokes1
1CompletedNot AvailableHealthy Volunteers6
1CompletedBasic ScienceEpilepsies1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentBenign Childhood Epilepsy With Centro-Temporal Spikes1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHuman Volunteers2
1CompletedTreatmentSeizures1
1, 2CompletedTreatmentDisorder of Fetus or Newborn / Seizures1
1, 2CompletedTreatmentEpilepsies / Malaria, Cerebral / Seizures1
1, 2CompletedTreatmentSeizures1
1, 2CompletedTreatmentSeizures / Term Neonates1
1, 2CompletedTreatmentTremor, Essential1
1, 2Not Yet RecruitingTreatmentNeonatal Convulsions1
1, 2RecruitingTreatmentNeonatal Convulsions1
2Active Not RecruitingTreatmentAlzheimer's Disease (AD)1
2Active Not RecruitingTreatmentSickle Cell Disorders1
2CompletedNot AvailableCranial Dystonia / Oromandibular Dystonia1
2CompletedNot AvailableDyskinesia, Medication-Induced1
2CompletedNot AvailableIdiopathic Parkinson's Disease1
2CompletedNot AvailablePostherpetic Neuralgia1
2CompletedBasic ScienceMild Cognitive Impairment (MCI)1
2CompletedPreventionEpilepsies / Post-Traumatic Seizure Disorder1
2CompletedSupportive CareBrain and Central Nervous System Tumors / Seizures1
2CompletedTreatmentAlcoholism / Anxiety Disorders / Generalized Anxiety Disorder (GAD) / Panic Disorders / Social Phobia1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS) / Motor Neurone Disease / Primary Lateral Sclerosis1
2CompletedTreatmentAnxiety Disorders1
2CompletedTreatmentBipolar Disorder (BD)1
2CompletedTreatmentChronic Idiopathic Axonal Polyneuropathy1
2CompletedTreatmentDependence, Cocaine / Opioid Dependence / Opioid Dependency1
2CompletedTreatmentDependence, Cocaine / Opioid Dependency1
2CompletedTreatmentEpilepsies6
2CompletedTreatmentEpilepsies / Malaria, Cerebral / Seizures1
2CompletedTreatmentEpilepsies / Partial onset seizure Epilepsy1
2CompletedTreatmentEpilepsy, Localization Related1
2CompletedTreatmentGrand Mal Status Epilepticus1
2CompletedTreatmentPhotosensitive Epilepsy1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2CompletedTreatmentSeizure, Absence1
2Not Yet RecruitingPreventionAPOE 41
2Not Yet RecruitingTreatmentGlioblastoma Multiforme (GBM)1
2Not Yet RecruitingTreatmentGlioma of Brain / Gliomas / Neoplasms, Brain1
2RecruitingOtherPsychosis / Schizo Affective Disorder / Schizophrenic Disorders / Schizophreniform1
2RecruitingTreatmentNeonatal Convulsions1
2RecruitingTreatmentNeuroblastomas1
2SuspendedTreatmentCervical Dystonia1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Acute Myelogenous Leukemia1
2TerminatedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
2Unknown StatusTreatmentLevodopa Induced Dyskinesia (LID)1
2Unknown StatusTreatmentRefractory seizure disorders1
2WithdrawnTreatmentSeizure, Alcohol Related1
2, 3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
2, 3TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
3Active Not RecruitingTreatmentAdverse Effects / Epilepsy, Localization Related1
3CompletedNot AvailableEpilepsy, Generalized1
3CompletedNot AvailableEpilepsy, Localization Related3
3CompletedNot AvailableEpilepsy, Tonic-Clonic1
3CompletedNot AvailableGeneralized Convulsive Epilepsy1
3CompletedPreventionAlcohol Dependence / Alcoholic Relapse1
3CompletedPreventionSubarachnoid Hemorrhage1
3CompletedTreatmentAlcohol Withdrawal Syndrome(AWS)1
3CompletedTreatmentEpilepsies7
3CompletedTreatmentEpilepsies / Grand mal Generalized tonic-clonic seizure3
3CompletedTreatmentEpilepsies / Partial1
3CompletedTreatmentEpilepsies / Partial onset seizure Epilepsy4
3CompletedTreatmentEpilepsy, Generalized1
3CompletedTreatmentEpilepsy, Localization Related4
3CompletedTreatmentEpilepsy, Tonic-Clonic1
3CompletedTreatmentGeneralized Convulsive Epilepsy1
3CompletedTreatmentPanic Disorders1
3CompletedTreatmentStatus; Epilepticus, Tonic-clonic1
3CompletedTreatmentTardive Dyskinesia1
3CompletedTreatmentPartial onset seizure Epilepsy1
3Not Yet RecruitingTreatment: Acute intraCerebral Haemorrhage1
3RecruitingHealth Services ResearchEpilepsies1
3RecruitingTreatmentBenzodiazepine Refractory Status Epilepticus1
3RecruitingTreatmentPartial onset seizure Epilepsy1
3TerminatedPreventionPost-Traumatic Seizure Disorder1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentDrug Resistant / Epilepsies1
3TerminatedTreatmentEpilepsies / Seizures1
3TerminatedTreatmentEpilepsy, Localization Related1
3Unknown StatusTreatmentEpilepsies1
3Unknown StatusTreatmentSeizures, Epileptic / Strokes1
3WithdrawnTreatmentEpilepsies / Refractory seizure disorders1
4Active Not RecruitingTreatmentEpilepsies1
4CompletedNot AvailableEpilepsies1
4CompletedNot AvailableEpilepsy, Localization Related2
4CompletedBasic ScienceHealthy Volunteers / Impaired Renal Function1
4CompletedPreventionManic State Associated With Corticosteroid Use / Memory Loss Associated With Corticosteroid Use1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentBody Dysmorphic Disorders1
4CompletedTreatmentDisseminated Sclerosis1
4CompletedTreatmentEpilepsies8
4CompletedTreatmentEpilepsies / Primary Brain Tumors1
4CompletedTreatmentEpilepsy, Localization Related4
4CompletedTreatmentGilles de la Tourette's Syndrome / Tic Disorders1
4CompletedTreatmentGrand mal Generalized tonic-clonic seizure1
4CompletedTreatmentPainful Polyneuropathy1
4CompletedTreatmentPain / Spinal Cord Injuries (SCI)1
4CompletedTreatmentParkinson's Disease (PD)1
4CompletedTreatmentSubarachnoid Hemorrhage / Traumatic Brain Injury (TBI)1
4RecruitingNot AvailableEpilepsies1
4RecruitingSupportive CareIntracranial Aneurysms / Seizures1
4RecruitingTreatmentBrain Cancer / Cancer of Brain / Cancer of the Brain / Neoplasms, Brain / Seizures1
4RecruitingTreatmentEpilepsies1
4RecruitingTreatmentGliomas1
4RecruitingTreatmentNeonatal Convulsions1
4RecruitingTreatmentSeizures / Traumatic Brain Injury (TBI)1
4TerminatedTreatmentIntracranial Aneurysms / Seizures1
4Unknown StatusTreatmentCSWS / Subclinical Sleep-Activated Epileptiform Activity1
4WithdrawnSupportive CareSeizures / Subarachnoid Hemorrhage1
4WithdrawnTreatmentParkinson's Disease (PD)1
Not AvailableCompletedNot AvailableEpilepsies / Seizures1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceAlzheimer's Disease (AD) / Seizures1
Not AvailableCompletedTreatmentAlcohol Abuse / Drug Abuse1
Not AvailableCompletedTreatmentChildhood Absence Epilepsy / Epilepsies / Seizures1
Not AvailableCompletedTreatmentDepression, Bipolar1
Not AvailableCompletedTreatmentFibromyalgia1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentPremenstrual Dysphoric Disorder1
Not AvailableCompletedTreatmentSeizures4
Not AvailableNot Yet RecruitingOtherSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableEpilepsies1
Not AvailableRecruitingNot AvailableEpileptic Encephalopathy1
Not AvailableRecruitingOtherSchizophrenic Disorders1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentAnoxic Encephalopathy / Cardiac Arrest / Refractory seizure disorders1
Not AvailableRecruitingTreatmentHaematological disorders / Haemoglobinopathies congenital / Immunodeficiencies1
Not AvailableTerminatedNot AvailableNeonatal Convulsions1
Not AvailableTerminatedTreatmentSubarachnoid Hemorrhage1
Not AvailableUnknown StatusTreatmentAdults With Tonic Clonic Seizures and/or Partial Seizures1
Not AvailableUnknown StatusTreatmentEpilepsies2
Not AvailableWithdrawnSupportive CareBrain and Central Nervous System Tumors / Seizures / Unspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Boca Pharmacal
  • Cardinal Health
  • Caremark LLC
  • Catalent Pharma Solutions
  • Cipla Ltd.
  • Cobalt Pharmaceuticals Inc.
  • Cypress Pharmaceutical Inc.
  • D.M. Graham Laboratories Inc.
  • Dept Health Central Pharmacy
  • DispenseXpress Inc.
  • Doctor Reddys Laboratories Ltd.
  • Fleming and Co.
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • Innoviant Pharmacy Inc.
  • InvaGen Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Lupin Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Oso Biopharmaceuticals Manufacturing LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Association
  • Pharmacy Service Center
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Quality Care
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandoz
  • Silarx Pharmaceuticals
  • Solco Healthcare US LLC
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Inc.
  • Torrent Pharmaceuticals
  • UCB Pharma
  • UDL Laboratories
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral1000 mg/1
Tablet, extended releaseOral1500 mg/1
Injection, solution, concentrateIntravenous100 mg/mL
TabletOral1000 mg/1
TabletOral250 mg
TabletOral500 mg
TabletOral750 mg
TabletOral750 mg/1
InjectionIntravenous10 mg/mL
InjectionIntravenous100 mg/mL
InjectionIntravenous15 mg/mL
InjectionIntravenous5 mg/mL
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous100 mg/mL
Injection, solutionIntravenous1000 mg/100mL
Injection, solutionIntravenous15 mg/mL
Injection, solutionIntravenous1500 mg/100mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous500 mg/100mL
Injection, solutionIntravenous500 mg/5mL
Injection, solution, concentrateIntravenous500 mg/5mL
SolutionOral100 mg/mL
SolutionOral1000 mg/10mL
SolutionOral1500 mg/15mL
SolutionOral500 mg/5mL
TabletOral500 mg/1
Tablet, extended releaseOral500 mg/1
Tablet, extended releaseOral750 mg/1
Tablet, film coatedOral1000 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
Tablet, film coated, extended releaseOral1000 mg/1
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral750 mg/1
Tablet, film coatedOral1000 mg
Tablet, film coatedOral250 mg
Tablet, film coatedOral500 mg
Tablet, film coatedOral750 mg
TabletOral250 mg/1
TabletOral1000 mg
Tablet, for suspensionOral1000 mg/1
Tablet, for suspensionOral250 mg/1
Tablet, for suspensionOral500 mg/1
Tablet, for suspensionOral750 mg/1
Prices
Unit descriptionCostUnit
Keppra 500 mg/5 ml vial9.28USD ml
Keppra 1000 mg tablet9.01USD tablet
Levetiracetam 1000 mg tablet7.18USD tablet
Keppra xr 750 mg tablet6.46USD tablet
Keppra xr 500 mg tablet6.43USD tablet
Keppra 500 mg tablet5.09USD tablet
Levetiracetam 750 mg tablet4.86USD tablet
Keppra 750 mg tablet4.74USD tablet
Keppra XR 500 mg 24 Hour tablet4.47USD tablet
Keppra 250 mg tablet3.62USD tablet
Levetiracetam 500 mg tablet3.59USD tablet
Levetiracetam 250 mg tablet2.93USD tablet
Apo-Levetiracetam 750 mg Tablet1.7USD tablet
Co Levetiracetam 750 mg Tablet1.7USD tablet
Pms-Levetiracetam 750 mg Tablet1.7USD tablet
Apo-Levetiracetam 500 mg Tablet1.23USD tablet
Co Levetiracetam 500 mg Tablet1.23USD tablet
Pms-Levetiracetam 500 mg Tablet1.23USD tablet
Apo-Levetiracetam 250 mg Tablet1.01USD tablet
Co Levetiracetam 250 mg Tablet1.01USD tablet
Pms-Levetiracetam 250 mg Tablet1.01USD tablet
Keppra 100 mg/ml Solution0.95USD ml
Levetiracetam 100 mg/ml Solution0.68USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8802142Yes2011-12-072031-12-07Us
US7858122No2008-09-172028-09-17Us
US6471992No1998-02-202018-02-20Us
US9463160No1998-02-202018-02-20Us
US9669009No2014-03-142034-03-14Us
US9339489No2014-03-142034-03-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-0.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility298.0 mg/mLALOGPS
logP-0.64ALOGPS
logP-0.59ChemAxon
logS0.24ALOGPS
pKa (Strongest Acidic)16.09ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.4 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity44.08 m3·mol-1ChemAxon
Polarizability17.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.988
Blood Brain Barrier+0.9821
Caco-2 permeable-0.6114
P-glycoprotein substrateSubstrate0.5137
P-glycoprotein inhibitor INon-inhibitor0.5612
P-glycoprotein inhibitor IINon-inhibitor0.8786
Renal organic cation transporterNon-inhibitor0.7024
CYP450 2C9 substrateNon-substrate0.8801
CYP450 2D6 substrateNon-substrate0.8184
CYP450 3A4 substrateNon-substrate0.5191
CYP450 1A2 substrateNon-inhibitor0.9394
CYP450 2C9 inhibitorNon-inhibitor0.7603
CYP450 2D6 inhibitorNon-inhibitor0.9471
CYP450 2C19 inhibitorNon-inhibitor0.8459
CYP450 3A4 inhibitorNon-inhibitor0.9669
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.8783
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.9305
Rat acute toxicity2.1707 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9206
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Pyrrolidine-2-ones / N-alkylpyrrolidines / Fatty amides / Tertiary carboxylic acid amides / Primary carboxylic acid amides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Alpha-amino acid or derivatives / Fatty amide / Pyrrolidone / 2-pyrrolidone / Fatty acyl / N-alkylpyrrolidine / Pyrrolidine / Tertiary carboxylic acid amide / Carboxamide group / Lactam
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
pyrrolidin-2-ones (CHEBI:6437)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Transmembrane transporter activity
Specific Function
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readi...
Gene Name
SV2A
Uniprot ID
Q7L0J3
Uniprot Name
Synaptic vesicle glycoprotein 2A
Molecular Weight
82694.665 Da
References
  1. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6. Epub 2004 Jun 21. [PubMed:15210974]
  2. Stahl SM: Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry. 2004 Sep;65(9):1162-3. [PubMed:15367040]
  3. Lambeng N, Grossmann M, Chatelain P, Fuks B: Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett. 2006 May 1;398(1-2):107-12. Epub 2006 Jan 24. [PubMed:16434140]
  4. Gillard M, Chatelain P, Fuks B: Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10. [PubMed:16556440]
  5. Newton HB, Dalton J, Goldlust S, Pearl D: Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol. 2007 Sep;84(3):293-6. Epub 2007 Apr 13. [PubMed:17431542]
  6. Johannessen Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22(1):27-47. [PubMed:18072813]
  7. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. De Smedt T, Raedt R, Vonck K, Boon P: Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev. 2007 Spring;13(1):43-56. [PubMed:17461889]
  2. Lukyanetz EA, Shkryl VM, Kostyuk PG: Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002 Jan;43(1):9-18. [PubMed:11879381]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
  2. Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11. [PubMed:18824002]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]

Drug created on June 13, 2005 07:24 / Updated on June 19, 2018 10:50